Description of 200 patients with SLE at the baseline study
| Baseline factor | |
| Age at diagnosis: mean (SD) years | 36.4 (11.8) |
| Disease duration: mean (SD) years | 11.7 (9.4) |
| Previous cerebrovascular event: n (%) | 16 (8) |
| Previous coronary event: n (%) | 7 (3.5) |
| Peripheral vascular disease: n (%) | 1 (0.5) |
| Ever ANA positive: n (%) | 188 (94) |
| Ever dsDNA positive: n (%) | 115 (57.5) |
| Ever aCL or LAC positive: n (%) | 73 (37) |
| Antiphospholipid syndrome: n (%) | 21 (10.5) |
| Current steroid therapy: n (%) | 106 (53) |
| SLEDAI-2K: median (IQR) | 1 (0–4) |
| SLICC damage index: median (IQR) | 0 (0–4) |
| Current antimalarial therapy: n (%) | 105 (52.5) |
| Current immunosuppressive therapy: n (%) | 74 (37) |
| Postmenopausal: n (%) | 94 (47) |
| Current smoker: n (%) | 40 (20) |
| Ex-smoker: n (%) | 57 (28.5) |
| Family history of premature CHD: n (%) | 53 (26.5) |
| Total cholesterol: median (IQR) mmol/L | 5.1 (4.3–6.0) |
| Fasting plasma glucose: median (IQR) mmol/L | 4.6 (4.3–4.9) |
| Systolic blood pressure: median (IQR) mm Hg | 126 (116–140) |
| Previous or current hypertension: n (%) | 83 (41.5) |
| Diabetes (%) | 6 (3.0) |
| BMI: median (IQR) kg/m2 | 26.0 (23.2–30.1) |
Hypertension: blood pressure of >140/90 or current treatment with antihypertensive drug. Hypercholesterolemia: total cholesterol >5.2 mmol/L or LDL cholesterol >3.2 mmol/L or on therapy. Family history of premature CVD: MI, angina or sudden death in a first-degree relative male <55 years or female <65 years. Diabetes mellitus: fasting plasma glucose >7.0 mmol/L or current diabetic therapy.
aCL, anticardiolipin antibody; BMI, Body Mass Index; CHD, coronary heart disease; CVD, cardiovascular disease; LAC, lupus anticoagulant; MI, myocardial infarction; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics.